Reimbursed Care Access in Eritrea

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

There is no publicly available evidence of national regulatory approval or a reimbursement program for esketamine (Spravato) in Eritrea; esketamine is marketed under strict supervised programs in higher‑income jurisdictions but no Eritrean marketing authorization record was identified in public sources. The global product labeling and approval context for Spravato is documented by the manufacturer and regulatory announcements (example: FDA and company press releases for other jurisdictions). # Note: absence of a public approval record for Eritrea was checked against international registries and country reporting; no national approval dossier or public reimbursement policy was found.

Ketamine is listed on the WHO Model List of Essential Medicines as an important anesthetic for health systems and is commonly the dissociative anesthetic available in low‑resource hospitals across many countries; this supports that ketamine is used in Eritrea within medical/surgical services as an anesthetic or analgesic where supply exists. #

Regulatory/coverage context: Eritrea is a party to the major UN drug control conventions, which obliges the state to control manufacture, distribution and prescription of narcotic and psychotropic drugs; those obligations are implemented through domestic controls that generally permit the medical use of internationally‑recognized essential medicines (such as injectable ketamine) while restricting non‑medical use. The United Nations treaty accession record confirms Eritrea’s participation in international drug control frameworks. #

Practical reimbursement and psychiatric‑use nuance: there is no public evidence of a national, government‑funded reimbursement program in Eritrea for ketamine when used off‑label for psychiatric indications (e.g., treatment‑resistant depression). In many low‑ and middle‑income countries, ketamine remains a hospital‑procured anesthetic on essential medicines lists and is not reimbursed for psychiatric administration (which, where it occurs, is typically private, out‑of‑pocket, or part of specialist care). WHO essential medicines guidance and global reporting indicate ketamine’s role as an anesthetic rather than a widely reimbursed psychiatric therapy. #

Operational and safety controls: where ketamine is used clinically it is typically subject to hospital procurement, pharmacy control, and administration by trained clinicians; psychiatric or repeated sub‑anesthetic regimens (for depression) are considered off‑label in jurisdictions without specific regulatory approval for that indication and would generally not be reimbursed by public schemes absent explicit national policy change. There is no public record of Eritrean national guidance authorizing or reimbursing ketamine for psychiatric indications.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no evidence of a national treatment program or reimbursement for ibogaine in Eritrea. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Traditional plant preparations that contain scheduled psychotropic compounds are typically controlled under national laws; no legal medical pathway or reimbursement exists in Eritrea. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no identified national medical authorization or reimbursement for mescaline in Eritrea. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. 2C family compounds are conventionally controlled worldwide and no Eritrean medical program for 2C compounds was identified. #